The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Open accessAbstract
BACKGROUND: A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). METHODS: This randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1:1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS: In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (6950 participants). During a mean follow-up period of 3.7 years, herpes zoster occurred in 23 HZ/su recipients and in 223 placebo recipients (0.9 vs. 9.2 per 1000 person-years). Vaccine efficacy against herpes zoster was 89.8% (95% confidence interval [CI], 84.2 to 93.7; P<0.001) and was similar in participants 70 to 79 years of age (90.0%) and participants 80 years of age or older (89.1%). In pooled analyses of data from participants 70 years of age or older in ZOE-50 and ZOE-70 (16,596 participants), vaccine efficacy against herpes zoster was 91.3% (95% CI, 86.8 to 94.5; P<0.001), and vaccine efficacy against postherpetic neuralgia was 88.8% (95% CI, 68.7 to 97.1; P<0.001). Solicited reports of injection-site and systemic reactions within 7 days after injection were more frequent among HZ/su recipients than among placebo recipients (79.0% vs. 29.5%). Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two study groups. CONCLUSIONS: In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of reactogenicity after one dose of mRNA-1273 was less than that observed for the recently approved recombinant adjuvanted zoster vaccine and after the second mRNA-1273 dose was similar to that of the zoster vaccine. 21,22”
From Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Vaccination against VZV is considered an effective approach to reduce the risk of shingles32.”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [32]
In the citing paper
“the AS01B-adjuvanted VZV gE subunit vaccine was highly effective irrespective of age”
From Successful and Maladaptive T Cell Aging (2017) · cites this paper as Cunningham et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The burden of disease in older people and implications for health policy and practice
Prince, M. J., Wu, F., Guo, Y., Gutiérrez‐Robledo, L. M., O'Donnell, M. J., Sullivan, R. J., & Yusuf, S. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61347-7 · Cited by 2,473
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Self-citationEfficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Self-citationSystematic review of incidence and complications of herpes zoster: towards a global perspective
Kawai, K., Gebremeskel, B. G., & Acosta, C. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004833 · Cited by 943
Yawn, B. P., Saddier, P., Wollan, P. C., Sauver, J. L. S., Kurland, M. J., & Sy, L. S. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1341 · Cited by 879
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Cohen, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1302674 · Cited by 737
Johnson, R. W., & Rice, A. S. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1403062 · Cited by 575
The incidence of herpes zoster in a United States administrative database
Insinga, R. P., Itzler, R. F., Pellissier, J. M., Saddier, P., & Nikas, A. A. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0150.x · Cited by 490
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Mechelen, M. V. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 318
Research works printed but not linked: 3
- Harpaz R, 2008, MMWR Recomm Rep, 57, 1
- Chen N, 2014, Cochrane Database Syst Rev, CD006866
- 2011, MMWR Morb Mortal Wkly Rep, 60, 1528
Cited by
Sorted by citations
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Colloca, L., Ludman, T., Bouhassira, D., Baron, R., Dickenson, A. H., Yarnitsky, D., Freeman, R. L., Truini, A., Attal, N., Finnerup, N. B., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.2 · Cited by 2,271
Neuropathic Pain: From Mechanisms to Treatment
Finnerup, N. B., Kuner, R., & Jensen, T. S. (2020) · Physiological Reviews · doi:10.1152/physrev.00045.2019 · Cited by 1,727
Furer, V., Rondaan, C., Heijstek, M. W., Agmon‐Levin, N., van Assen, S., Bijl, M., Breedveld, F. C., D’Amelio, R., Dougados, M., Kapetanovic, M. C., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215882 · Cited by 859
Dooling, K. L., Guo, A., Patel, M., Lee, G. M., Moore, K. L., Belongia, E. A., & Harpaz, R. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6703a5 · Cited by 633
Metadata
- Authors
- Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., Vanden Abeele, C., Vesikari, T., Watanabe, D., Zahaf, T., Ahonen, A., Athan, E., Barba-Gomez, J. F., Campora, L., de Looze, F., Downey, H. J., Ghesquiere, W., Gorfinkel, I., Korhonen, T., Leung, E., McNeil, S. A., Oostvogels, L., Rombo, L., Smetana, J., Weckx, L., Yeo, W., & Heineman, T. C.
- Affiliations
- The University of Sydney (AU)
- Uppsala University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-09-15
- Volume
- 375
- Issue
- 11
- Pages
- 1019-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2519957152
- Cited by
- 1,070
- References
- 31
- Citations by year
- 2026: 96 · 2025: 124 · 2024: 107 · 2023: 97 · 2022: 91 · 2021: 120 · 2020: 94 · 2019: 117 · 2018: 138 · 2017: 75 · 2016: 11
- FWCI
- 106.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Novo Nordisk
- Astellas Pharma
- H. Lundbeck A/S
- Sanofi Pasteur
- Topics
- Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
- Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- herpes zoster, postherpetic neuralgia, vaccine efficacy, older adults, AS01B adjuvant, vaccine safety, herpes zoster incidence, vaccine adverse events, immunosenescence, immunogenicity
- MeSH terms
- Aged, Aged, 80 and over, Double-Blind Method, Female, Herpes Zoster, Humans, Male, Middle Aged, Risk, Vaccines, Subunit, Neuralgia, Postherpetic, Herpes Zoster Vaccine, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
